valproic acid has been researched along with Bone Neoplasms in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Futani, H; Nishiura, H; Sawai, T; Tachibana, T; Yamanegi, K | 1 |
| Bunce, CM; Ellington, MA; Johnson, WE; Khanim, FL; MacKay, HL; Sheard, JJ; Snow, MD; Southam, AD | 1 |
| Hayashi, K; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kimura, H; Kiyuna, T; Miwa, S; Murakami, T; Tsuchiya, H; Yamamoto, N | 1 |
| Desiderio, V; La Noce, M; Lombardi, A; Mele, L; Paino, F; Papaccio, F; Papaccio, G; Regad, T; Tirino, V | 1 |
| Fujihara, Y; Futani, H; Kobayashi, K; Kumanishi, S; Nakasho, K; Nishiura, H; Yamanegi, K; Yoshiya, S | 1 |
| Li, Q; Teng, Y; Wang, CK; Xie, G; Yu, XD | 1 |
| Hayashi, K; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N | 1 |
| Futani, H; Hata, M; Kato-Kogoe, N; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamane, J; Yamanegi, K | 1 |
| Hughes, DP | 1 |
| Fukunaga, S; Futani, H; Hata, M; Kato-Kogoe, N; Kobayashi, K; Nakasho, K; Nishioka, T; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamane, J; Yamanegi, K | 1 |
| Ptitsyn, AA; Thamm, DH; Wittenburg, LA | 1 |
| Fukunaga, S; Futani, H; Hata, M; Kobayashi, K; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamane, J; Yamanegi, K | 1 |
1 review(s) available for valproic acid and Bone Neoplasms
| Article | Year |
|---|---|
How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize.
Topics: Basic Helix-Loop-Helix Transcription Factors; Bone Development; Bone Neoplasms; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Neoplasm Invasiveness; Osteosarcoma; Receptors, Notch; Signal Transduction; Transcription Factor HES-1; Valproic Acid | 2009 |
11 other study(ies) available for valproic acid and Bone Neoplasms
| Article | Year |
|---|---|
Sodium Valproate Enhances Semaphorin 3A-mediated Anti-angiogenesis and Tumor Growth Inhibition in Human Osteosarcoma Cells.
Topics: Bone Neoplasms; Histone Deacetylase Inhibitors; Humans; Neovascularization, Pathologic; Neuropilin-1; Osteosarcoma; Semaphorin-3A; Valproic Acid | 2023 |
Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem cells.
Topics: Bezafibrate; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Repositioning; Drug Therapy, Combination; Fatty Acid Synthases; Humans; Medroxyprogesterone Acetate; Mesenchymal Stem Cells; Osteosarcoma; Stearoyl-CoA Desaturase; Up-Regulation; Valproic Acid | 2021 |
Antimetastatic Efficacy of the Combination of Caffeine and Valproic Acid on an Orthotopic Human Osteosarcoma Cell Line Model in Nude Mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Caffeine; Cell Death; Cell Line, Tumor; Cell Survival; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Osteosarcoma; Valproic Acid | 2017 |
HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.
Topics: Animals; Azacitidine; Bone Neoplasms; Cell Line, Tumor; DNA Methylation; Heterografts; Histone Deacetylase 2; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Osteosarcoma; Transfection; Valproic Acid | 2018 |
Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells.
Topics: Bone Neoplasms; Cell Line; Cell Line, Tumor; Drug Synergism; Endothelial Cells; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Hydralazine; Neovascularization, Pathologic; Osteosarcoma; Receptors, Tumor Necrosis Factor, Member 25; RNA, Messenger; Transcription, Genetic; Tumor Necrosis Factor Ligand Superfamily Member 15; Valproic Acid; Vascular Endothelial Growth Factor A | 2019 |
Chloroquine and valproic acid combined treatment in vitro has enhanced cytotoxicity in an osteosarcoma cell line.
Topics: Anticonvulsants; Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Neoplasms; Caspases; Cell Cycle; Cell Proliferation; Chloroquine; Drug Synergism; Histone Deacetylase Inhibitors; Humans; In Vitro Techniques; Osteosarcoma; Reactive Oxygen Species; Tumor Cells, Cultured; Tumor Stem Cell Assay; Valproic Acid | 2013 |
Non-toxic Efficacy of the Combination of Caffeine and Valproic Acid on Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Caffeine; Caspase 3; Caspase 7; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Histone Deacetylase Inhibitors; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Osteosarcoma; Tibia; Valproic Acid | 2016 |
Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death.
Topics: Antibodies; Bone Neoplasms; Cell Death; Cell Proliferation; Down-Regulation; Drug Evaluation, Preclinical; Drug Synergism; Enzyme Inhibitors; fas Receptor; Histone Deacetylases; Histones; Humans; Osteosarcoma; Solubility; Tumor Cells, Cultured; Valproic Acid | 2009 |
Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity.
Topics: Antigens, Surface; Bone Neoplasms; Cell Line, Tumor; Cell Membrane; Combined Modality Therapy; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class I; Histone Deacetylase Inhibitors; Humans; Immunity, Cellular; Immunotherapy; Killer Cells, Natural; Ligands; NK Cell Lectin-Like Receptor Subfamily K; Osteosarcoma; Protein Isoforms; Solubility; Up-Regulation; Valproic Acid | 2010 |
A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Dogs; Down-Regulation; Endothelin-1; Gene Expression Profiling; Histone Deacetylase Inhibitors; NAD(P)H Dehydrogenase (Quinone); Osteosarcoma; Proteasome Inhibitors; Real-Time Polymerase Chain Reaction; Systems Biology; Valproic Acid | 2012 |
Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells.
Topics: Bone Neoplasms; Cell Line, Tumor; Dipeptides; Down-Regulation; Histocompatibility Antigens Class I; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Membrane Proteins; Osteosarcoma; RNA Interference; RNA, Messenger; RNA, Small Interfering; Valproic Acid | 2012 |